Further, they offer a preclinical proof of concept for the use of MRS to measure lactate as a non-invasive metabolic biomarker for PD response to MEK1/2 inhibition in BRAF-driven cancers.
metabolites and glycolytic intermediates (7) ) which are altered with chemotherapy and various molecularly-targeted anti-cancer agents (8, 9) .
The increased glycolytic activity of cancer cells under normoxic conditions, known as the "Warburg effect", is characterized by increased glucose uptake and lactate production (10) . This allows fast-growing cancer cells to shunt glycolytic intermediates into anabolic reactions while the acid produced aids tumor invasion and stroma destruction (11) . Increased tumor lactate correlates with poor prognosis in some cases of brain, breast, lung and liver cancers (12) . Furthermore, in human cervical cancer, high tumor lactate concentration is correlated with metastasis and decreased survival, whereas low tumor lactate is associated with increased survival (13) .
Glycolysis is also regulated by oncogenic signaling and glycolytic alterations occur following inhibition of BCR-ABL (14) , PDGF receptor (15) and PI3K (16) .
RAS activation increases glycolysis in rat fibroblasts (17, 18) and the ERK1/2 transcriptional targets C-MYC and NF-kB (19) upregulate glycolytic enzyme expression (20) and increase glucose transporter expression (21) , respectively.
Moreover, human cancer cells harboring oncogenic BRAF exhibit increased C-MYC expression (22) , glucose uptake and lactate production (23).
Therefore, we hypothesized that inhibition of MEK1/2 could impact on the levels of lactate formation in human cancer cells that may be detected by MRS. Here we test this hypothesis and a) assess whether inhibition of MEK1/2 signaling in human cancer cells alters lactate levels as detected by MRS and b) explore the underlying mechanisms for our observations. Furthermore, since highly activating BRAF mutations confer sensitivity to MEK1/2 signaling inhibitors (6), we also assess the dependency of the observed effects on BRAF mutation status. and re-suspended in D2O+TSP as above. 1 H MRS data were acquired on a Bruker 500MHz spectrometer at 25°C. Spectral processing and metabolite quantification were performed as previously described (25).
Colorimetric lactate measurements
WM266.4, A2058, HT29, RKO, colo829, DO4, HT55 and DLD1 cells were grown in 96 well plates and media lactate levels following a 24h treatment with 0.1% DMSO (control) or 1μM CI-1040 monitored with a colorimetric assay according to manufacturer's protocol (Cambridge BioSciences). Readings were corrected for viable cell content measured with the MTS assay.
Glucose uptake
WM266.4 cells were incubated for 22h with CI-1040 followed by 2h in 1µM CI-1040+10µM 2-NBDG fluorescent glucose analogue (Invitrogen). The final 2h
incubation was performed in FBS-and glucose-free media. Cells were re-suspended in 1ml ice-cold PBS with 1µg/ml propidium iodide and analyzed at 4°C on a FACSAria TM (BD Biosciences) using 488nm excitation and 530nm emission.
Hexokinase inhibition and c-Myc knockdown
To inhibit hexokinase, WM266.4 and CHL-1 cells were treated for 24h with 1mM of the glucose analogue 2-deoxyglucose (2-DG, Sigma-Aldrich). For c-Myc knockdown, WM266.4 cells were reverse-transfected with 2nM of negative control siRNA (AllStars-target sequence proprietary) or C-MYC-directed siRNA (target sequence:
CCCAAGGTAGTTATCCTTAAA) for 48h in 0.25% HiPerFect reagent using manufacturer's protocol (Qiagen). Media samples were analyzed by 1 H MRS for lactate as described above. Importantly, addition of IL-3 to the growth media, which disrupts the BRAFdependency (24), abrogated the effect on lactate E that was observed in the absence of IL-3 following CI-1040 treatment (98±6%, p=0.5).
These data demonstrate that it is the dependency of cells on mutant BRAF that controls the decrease in lactate E following MEK1/2 inhibition.
CI-1040 reduces glucose metabolism in BRAF V600E/V600D but not BRAF WT human melanoma cells
In cancer cells, the major route for lactate production is glucose metabolism (12) .
Concentrating on melanoma cells, we assessed the effect of CI-1040 on glucose The decrease in hexokinase-II expression is consistent with reduced glucose utilization for the generation of downstream glycolytic intermediates including pyruvate, and consequently lactate. Indeed exposure of WM266.4 and CHL-1 cells to the glycolysis and hexokinase inhibitor 2-DG also decreased lactate E levels (Fig.4A) .
We also observed a reduction in c-Myc expression in BRAF-driven WM266.4
and SKMEL28 cells but not in BRAF WT CHL-1 or DO4 cells (Fig.3E) . siRNA- These results indicate that the reduction in lactate E observed after MEK1/2 inhibition is associated with down-regulation of glucose metabolism, and particularly hexokinase-II expression, which could result from c-Myc depletion. This effect was only observed in BRAF-driven melanoma cells.
MEK1/2 inhibition with selumetinib reduces lactate levels in BRAF-driven melanoma xenografts
WM266.4 melanoma xenografts were used to monitor the in vivo effects of MEK1/2 inhibition by selumetinib on tumor lactate. This drug was chosen as it was in clinical testing when the research was being conducted.
After 3 days of dosing, selumetinib-treated WM266.4 tumors were not significantly different in volume compared to pre-treatment values (100±22%, p=0.98) indicating a growth arrest. In contrast, vehicle-treated tumors progressed to 143±18% (p=0.002).
Immunoblotting confirmed MEK1/2 inhibition in tumor xenografts as shown by reduced P-ERK1/2 and pRB expression (Fig.5A) . 1 H MRS of excised tumor tissue revealed a 55±23% reduction in lactate concentration in the drug-treated tumors relative to controls (p=0.0001, Fig.5B ). Furthermore, the ratio of lactate to total metabolites present in the 0.8-3.1ppm spectral range, containing many glycolytic intermediates and amino acids, was also reduced to a similar level (Fig.5B) . Thus the decline in lactate content is not simply a reflection of reduced overall metabolite 
Discussion
The BRAF inhibitor vemurafenib has recently gained FDA approval for the treatment of BRAF-driven melanoma (33) and many other BRAF and MEK1/2 inhibitors are undergoing clinical development (34) .
Earlier studies have shown that oncogenic RAS increases the glycolytic activity of murine fibroblasts and human cancer cells (35, 36) . The ERK1/2 target cMyc increases lactate dehydrogenase (LDH)-A expression and lactate generation in rat fibroblasts (37) , and activation of NF-kB, another ERK1/2 target, in mouse embryonic fibroblasts increases glucose transporter expression and lactate production (21) . Furthermore, human cancer cells with high activity BRAF mutants exhibit enhanced glucose uptake and lactate production (23).
We therefore hypothesized that inhibition of MEK1/2 signaling decreases lactate production in human cancer cells allowing monitoring of drug effects by MRS. A decrease in lactate production has previously been observed in human breast cancer cells following PI3K-AKT signaling inhibition (39) . With MEK1/2 inhibitor treatment, no effects on P-AKT levels were observed in WM266.4 cells (Supplementary Fig.S5 ). Hence, the treatment-induced decrease in lactate E observed here could not be due to PI3K-AKT inhibition. effectors (14) (15) (16) . Whether the differential lactate response observed here is linked to compensatory effects from such proteins or from alternative signaling or metabolic pathways warrants further investigation.
Next we set out to explore the metabolic processes underlying the lactate E effect following MEK1/2 inhibition in human melanoma cells. The predominant source for lactate production in cancer cells is glucose metabolism. Glucose is taken up into cells via glucose transporters then phosphorylated via hexokinase, particularly hexokinase-II, to produce glucose-6-phosphate. This is subsequently metabolized via a multi-step process to pyruvate which is then converted to lactate via LDH (12) .
Pyruvate can also be metabolized to other intermediates, mainly alanine, acetyl-CoA and oxaloacetate (42) . No significant changes in 1 H MRS-detectable alanine were observed in CI-1040-treated BRAF V600D WM266.4 melanoma cells that could indicate pyruvate-alanine transamination and which could lead to decreased lactate E (data not shown). Detailed metabolic flux analysis is required to assess whether the effects observed here lead to altered flux to oxaloacetate and/or acetyl-CoA.
We assessed glucose metabolism by measuring its uptake into cells (using 1 H MRS and 2-NBDG) and the expression of hexokinase-I/II using immunoblotting. CAN-12-1969 of other targeted drugs known to inhibit hexokinase-II, and potentially also c-Myc, e.g. mTOR and PDGF receptor inhibitors (15, 53) .
In summary, we show that selective MEK1/2-targeted therapeutics decrease lactate Tables   Table 1. Cell lines used, their tissue of origin and BRAF/RAS mutational status.
Cell line
Tissue type BRAF mutation status 
RAS mutation status
Human ------------------------- ------ DO4 CHL-1 HCT116 HT55 DLD1 MDA-MB231 WM266.4 SKMEL-28 A2058 Colo829 HT29 RKO Murine ------------------------- ------ Ba/F3 ----------------------- ------ Melanoma----------------------- ------ Haematopoietic ----------------------- ------ WT WT WT WT WT G464V V600D V600E V600E V600E V600E V600E ----------------------- ------ V600E/WT ----------------------- ------ NRASQ61L WT KRASG13D WT KRASG13D KRASG13D WT WT WT WT WT WT ----------------------- ------ WT
